SWOG clinical trial number
S0224
Phase II Study of Weekly Docetaxel in Patients with Advanced Epidermoid Carcinoma of the Penis
Closed
Phase
Accrual
5%
Research committees
Genitourinary Cancer
Treatment
Docetaxel
Eligibility Criteria Expand/Collapse
Pt must have bx proven epidermoid Ca of the penis w/distant mets (M1) or pathologically proven regional nodal mets (N1-3). Pt must have mx disease assessed w/in 28 days prior to reg. Pt may have rec'd prior RT, but at least 28 days must have elapsed. Pt must not have had any prior chemo for penile Ca. Pt must not have Gr 2 or greater peripheral neuropathy. Pt must not have hypersensitivity to drug formulated w/polysorbate-80. Pt must have AGC >/= 1500; PLT >/= 100,000; WBC >/= 3000 w/in 28 days prior to reg. Pt must have SGOT </= 2.5 x ULN and Alk Phos </= 4 X ULN and meet add'l criteria in Sect 5.8 of the protocol. Pt must have Zubrod P S </= 2.
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase